These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6650125)

  • 1. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations.
    Kristensen O; Klitgaard NA; Jönsson B; Sindrup S
    Acta Neurol Scand; 1983 Sep; 68(3):145-50. PubMed ID: 6650125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients.
    Klitgaard NA; Kristensen O
    Eur J Clin Pharmacol; 1986; 31(1):91-4. PubMed ID: 3780834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of oxcarbazepine.
    May TW; Korn-Merker E; Rambeck B
    Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia.
    Patsalos PN; Elyas AA; Zakrzewska JM
    Eur J Clin Pharmacol; 1990; 39(4):413-5. PubMed ID: 2076729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers.
    Theisohn M; Heimann G
    Eur J Clin Pharmacol; 1982; 22(6):545-51. PubMed ID: 7128666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.
    Tartara A; Galimberti CA; Manni R; Morini R; Limido G; Gatti G; Bartoli A; Strada G; Perucca E
    Br J Clin Pharmacol; 1993 Oct; 36(4):366-8. PubMed ID: 12959317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gas chromatographic/mass spectrometric assays for oxcarbazepine and its main metabolites, 10-hydroxy-carbazepine and carbazepine-10,11-trans-diol.
    von Unruh GE; Paar WD
    Biomed Environ Mass Spectrom; 1986 Dec; 13(12):651-6. PubMed ID: 2952188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother.
    Bülau P; Paar WD; von Unruh GE
    Eur J Clin Pharmacol; 1988; 34(3):311-3. PubMed ID: 3396622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia.
    Zakrzewska JM; Patsalos PN
    J Neurol Neurosurg Psychiatry; 1989 Apr; 52(4):472-6. PubMed ID: 2738589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.
    Degen PH; Flesch G; Cardot JM; Czendlik C; Dieterle W
    Biopharm Drug Dispos; 1994 Aug; 15(6):519-26. PubMed ID: 7993989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
    Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
    Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.
    Rouan MC; Lecaillon JB; Godbillon J; Menard F; Darragon T; Meyer P; Kourilsky O; Hillion D; Aldigier JC; Jungers P
    Eur J Clin Pharmacol; 1994; 47(2):161-7. PubMed ID: 7859804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state.
    Cardot JM; Degen P; Flesch G; Menge P; Dieterle W
    Biopharm Drug Dispos; 1995 Oct; 16(7):603-14. PubMed ID: 8785383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The accuracy of oxcarbazepine (OXC) quantification by a liquid chromatography/tandem mass spectrometry method is influenced by the ion source fragmentation of its metabolite trans-diol-carbazepine (DHD).
    Corso G; D'Apolito O; Paglia G
    Rapid Commun Mass Spectrom; 2007; 21(2):269-72. PubMed ID: 17167814
    [No Abstract]   [Full Text] [Related]  

  • 15. High-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of carbamazepine, oxcarbazepine, and their main metabolites in human serum.
    Lionetto L; Casolla B; Cavallari M; Tisei P; Buttinelli C; Simmaco M
    Ther Drug Monit; 2012 Feb; 34(1):53-8. PubMed ID: 22210100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The distribution of 10-hydroxy carbazepine in blood compartments.
    Jung H; Noguez A; Mayet L; Fuentes I; González-Esquivel DF
    Biopharm Drug Dispos; 1997 Jan; 18(1):17-23. PubMed ID: 9008266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
    Sattler A; Schaefer M; May TW
    Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.
    Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
    Eur J Clin Pharmacol; 1989; 37(1):69-74. PubMed ID: 2591466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of carbamazepine in plasma and saliva of man.
    Pynnönen S
    Acta Pharmacol Toxicol (Copenh); 1977 Nov; 41(5):465-71. PubMed ID: 579557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.
    Larkin JG; McKee PJ; Forrest G; Beastall GH; Park BK; Lowrie JI; Lloyd P; Brodie MJ
    Br J Clin Pharmacol; 1991 Jan; 31(1):65-71. PubMed ID: 2015172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.